Semaglutide (Ozempic)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Ozempic: type 2 diabetes in adults
Product first approved 2018novonordisk.com
EU
  • Ozempic: type 2 diabetes mellitus
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (48)
Atherosclerotic Cardiovascular Disease
Chronic Kidney Disease
NCT06058585 · The George Institute
2024-09-04 – 2029-12-31 · Chronic Kidney Diseases
What this study did
NCT04741074 · Geisinger Clinic
2021-07-23 – 2023-01-31 · CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
What this study did
Type 2 Diabetes
NCT07581145 · Ole Lander Svendsen
2026-04-24 – 2029-12 · Foot Ulcer Due to Type 2 Diabetes Mellitus
What this study did
NCT07428746 · Emory University
2026-05-07 – 2028-11 · Diabetes Mellitus, Type 2
What this study did
NCT03811561 · Novo Nordisk A/S
2019-05-08 – 2027-11-07 · Diabetes Mellitus, Type 2
What this study did
NCT07059377 · Ottawa Heart Institute Research Corporation
2026-02-13 – 2027-07 · Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence
What this study did
NCT05649137 · Novo Nordisk A/S
2023-01-04 – 2024-12-13 · Obesity, Diabetes Mellitus, Type 2
What this study did
NCT05816057 · Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
2022-07-25 – 2023-10-31 · Diabetes Mellitus, Type 2
What this study did
NCT05478252 · Novo Nordisk A/S
2022-08-03 – 2023-09-18 · Diabetes Mellitus, Type 2
What this study did
NCT06489457 · University Medical Centre Ljubljana
2020-09-20 – 2023-06-30 · Type 2 Diabetes Mellitus, Obesity, Functional Hypogonadism
What this study did
NCT03689374 · Novo Nordisk A/S
2018-10-01 – 2021-02-22 · Diabetes Mellitus, Type 2
What this study did
NCT04287179 · Novo Nordisk A/S
2020-03-09 – 2021-01-25 · Diabetes Mellitus, Type 2
What this study did
NCT03061214 · Novo Nordisk A/S
2017-08-28 – 2019-04-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03136484 · Novo Nordisk A/S
2017-03-15 – 2018-11-16 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03191396 · Novo Nordisk A/S
2017-06-27 – 2018-08-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03086330 · Novo Nordisk A/S
2017-03-15 – 2018-08-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02648204 · Novo Nordisk A/S
2016-01-06 – 2017-05-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02207374 · Novo Nordisk A/S
2014-08-04 – 2016-02-27 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02254291 · Novo Nordisk A/S
2014-10-02 – 2015-11-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07770282 · All India Institute of Medical Sciences, Bhubaneswar
2026-12-01 – 2030-12-30 · Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin Resistance
What this study did
NCT05569772 · Universitaire Ziekenhuizen KU Leuven
2023-09-14 – 2030-05 · Glucose Intolerance After a Recent History of Gestational Diabetes
What this study did
NCT07218354 · VA Office of Research and Development
2026-07-28 – 2030-03-30 · Alcohol Use Disorder
What this study did
NCT06082063 · Steno Diabetes Center Copenhagen
2024-07-01 – 2029-07-01 · Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure
What this study did
NCT05305794 · Centre Hospitalier Universitaire Dijon
2022-07-12 – 2028-08 · Double Diabetes
What this study did
NCT05819853 · University of Colorado, Denver
2023-11-03 – 2028-06-30 · PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
What this study did
NCT06788626 · Wei Hu
2025-02 – 2028-02 · Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment
What this study did
NCT07030621 · RenJi Hospital
2025-07-01 – 2028-01-31 · Acute Ischemic Stroke
What this study did
NCT05819138 · University of Colorado, Denver
2023-06-21 – 2027-12-01 · Diabetes Mellitus, Type 1
What this study did
NCT05586802 · Georgios Papadakis
2023-03-21 – 2027-04-30 · Klinefelter Syndrome
What this study did
NCT06894784 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2025-04 – 2027-01 · Diabetes Type 1
What this study did
NCT07820111 · Zagazig University
2025-10-18 – 2026-03-17 · Obese Diabetics, Obese Non Diabetic
What this study did
NCT05071417 · Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
2021-11 – 2025-12 · Atheroscleroses, Coronary
What this study did
NCT05891496 · Novo Nordisk A/S
2023-06-20 – 2025-09-08 · Alzheimers Disease
What this study did
NCT06361823 · Capital Medical University
2024-05-01 – 2025-01-01 · Idiopathic Intracranial Hypertension
What this study did
NCT04447859 · Tel-Aviv Sourasky Medical Center
2020-02-23 – 2022-09-10 · Diabetes type2
What this study did
Phase 2/3 (7)
Other / comorbidity
NCT07891156 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2026-10-13 – 2028-10-01 · Type 1 Diabetes, Overweight , Obesity
What this study did
NCT06387199 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2024-12-01 – 2027-12 · Type 1 Diabetes, Diabetes Mellitus
What this study did
Triple Therapy in T1DMactive not recruiting
NCT03899402 · State University of New York at Buffalo
2019-05-01 – 2026-06-30 · Type 1 Diabetes Mellitus
What this study did
NCT05646199 · University of Hull
2025-03-01 – 2025-12-30 · Polycystic Ovary Syndrome
What this study did
NCT06619015 · Esbjerg Hospital - University Hospital of Southern Denmark
2025-04-01 – 2025-04-01 · Obesity, Appetite Regulation, PreDiabetes
What this study did
NCT05788965 · University of Minnesota
2023-10-16 – 2024-12-31 · Cystic Fibrosis, Cystic Fibrosis-related Diabetes
What this study did
NCT05205928 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2022-10-02 – 2024-06-30 · Type 1 Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 2 (46)
Chronic Kidney Disease
NCT05822609 · University of Washington
2024-04-05 – 2027-12 · Diabetic Kidney Disease, Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT05067621 · Yale University
2023-07-17 – 2027-01 · Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
What this study did
NCT04451837 · Region Skane
2020-09-10 – 2026-12-31 · Type2 Diabetes
What this study did
NCT06005012 · University of California, San Diego
2023-07-25 – 2026-12-31 · Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
What this study did
NCT06974825 · BrightGene Bio-Medical Technology Co., Ltd.
2023-08-30 – 2024-08-13 · Type 2 Diabetes
What this study did
NCT05486065 · Novo Nordisk A/S
2022-08-08 – 2023-12-13 · Diabetes Mellitus, Type 2
What this study did
NCT05144984 · Novo Nordisk A/S
2021-11-29 – 2023-03-23 · Diabetes Mellitus, Type 2
What this study did
NCT04143945 · Novo Nordisk A/S
2019-10-28 – 2020-01-04 · Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
What this study did
NCT04007107 · Novo Nordisk A/S
2019-06-27 – 2019-09-04 · Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
What this study did
NCT02461589 · Novo Nordisk A/S
2015-09-21 – 2016-10-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00696657 · Novo Nordisk A/S
2008-06-03 – 2009-02-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07204249 · San Francisco Department of Public Health
2026-02-26 – 2030-02-15 · Methamphetamine-dependence
What this study did
NCT07430332 · Children's Hospital Medical Center, Cincinnati
2027-09-01 – 2030-01-01 · Stage 1 Diabetes Mellitus, Type 1
What this study did
NCT07325500 · The University of Texas Health Science Center, Houston
2026-02-12 – 2029-06-30 · Weight Gain
What this study did
NCT07879612 · Massachusetts General Hospital
2027-01-10 – 2029-03-30 · Cannabis Use Disorder, Cue-reactivity
What this study did
NCT07227948 · The University of Texas Health Science Center, Houston
2026-01-15 – 2029-02-28 · Cocaine Use Disorder
What this study did
NCT07511543 · Population Health Research Institute
2026-10-31 – 2029-01-31 · Ischemic Stroke
What this study did
NCT07613437 · Chinese University of Hong Kong
2026-06-15 – 2028-12-31 · Intracerebral Hemorrhage
What this study did
NCT07614412 · Ministry of Health, Saudi Arabia
2027-01-01 – 2028-12-31 · Type 1 Diabetes Mellitus
What this study did
NCT06411210 · Yale University
2024-07-16 – 2028-06-30 · Diabetes type1, Obesity
What this study did
NCT07523633 · Anders Fink-Jensen, MD, DMSci
2026-04-30 – 2028-04-30 · Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis Addiction
What this study did
NCT07202247 · City of Hope Medical Center
2025-11-05 – 2028-04-09 · Prostate Carcinoma, Recurrent Prostate Carcinoma
What this study did
NCT05938712 · University Health Network, Toronto
2023-10-24 – 2028-03-01 · Kidney Transplant Recipients
What this study did
NCT05630586 · Aarhus University Hospital
2023-04-12 – 2027-12 · Acute Ischemic Stroke
What this study did
NCT06639464 · Brigham and Women's Hospital
2025-06-02 – 2027-09-15 · Opioid Use Disorder
What this study did
NCT06691243 · University of Maryland, Baltimore
2025-08-07 – 2027-07 · Cocaine Use Disorder, HIV
What this study did
NCT07040592 · Yale University
2026-01-15 – 2027-06-30 · Alcohol Use Disorder (AUD), HIV
What this study did
NCT06548490 · Milton S. Hershey Medical Center
2025-01-27 – 2027-04-30 · Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
What this study did
NCT06015893 · National Institute on Drug Abuse (NIDA)
2023-10-17 – 2027-03-31 · Addiction, Alcohol Use Disorder
What this study did
NCT07509112 · Kirby Institute
2026-09 – 2027-03 · Methamphetamine Use Disorder
What this study did
Semaglutide in Auto-HSCTnot yet recruiting
NCT06449625 · Klaus Gottlob Müller
2024-08-12 – 2027-02-01 · Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity
What this study did
NCT05424003 · University of Virginia
2024-02-22 – 2026-08-01 · NAFLD
What this study did
NCT07610174 · Kafrelsheikh University
2025-06-02 – 2026-04-29 · Heart Failure, Heart Valve Prosthesis
What this study did
NCT07871799 · Sheba Medical Center
2025-11-17 – 2026-02-25 · Healthy Aging
What this study did
NCT06762314 · Mostafa Bahaa
2025-01-20 – 2026-01-20 · Diabetes
What this study did
NCT06409130 · Novo Nordisk A/S
2024-05-20 – 2026-01-12 · Alcohol-related Liver Disease
What this study did
NCT05891587 · Oklahoma State University Center for Health Sciences
2023-07-07 – 2025-10-01 · Alcohol Use Disorder
What this study did
NCT03659682 · Oslo University Hospital
2019-01-02 – 2024-12-31 · Parkinson Disease
What this study did
NCT04466345 · University Health Network, Toronto
2021-10-06 – 2024-12-27 · Major Depressive Disorder
What this study did
NCT05920889 · Chinese University of Hong Kong
2023-08-01 – 2024-10-25 · Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases
What this study did
NCT05537233 · Viral N. Shah
2023-04-11 – 2024-08-06 · Type 1 Diabetes, Obesity
What this study did
NCT05530577 · University of North Carolina, Chapel Hill
2022-10-07 – 2024-05-13 · Tobacco Use Disorder, Nicotine Addiction
What this study did
NCT05193578 · Jan Frystyk
2022-01-01 – 2024-05-01 · Schizophrenia, Prediabetic State
What this study did
NCT05520775 · University of North Carolina, Chapel Hill
2022-09-02 – 2024-04-19 · Alcohol Use Disorder, Cigarette Smoking
What this study did
NCT04216589 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-02-19 – 2023-09-15 · HIV Infections, Non-Alcoholic Fatty Liver Disease
What this study did
NCT04615871 · Vladimír Džavík
2021-09-10 – 2022-03-31 · Covid19, Myocardial Injury
What this study did
Phase 1/2 (5)
Type 2 Diabetes
NCT07563699 · Mapi Pharma Ltd.
2026-08-09 – 2028-06 · Diabete Type 2
What this study did
NCT07374328 · Second Affiliated Hospital of Guangzhou Medical University
2025-06-01 – 2026-08-31 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07651319 · The Methodist Hospital Research Institute
2026-09-01 – 2029-12 · Alzheimer Dementia (AD)
What this study did
NCT06057077 · Ministry of Health, Saudi Arabia
2024-01-01 – 2024-12-31 · Type 1 Diabetes
What this study did
NCT04702516 · Morten Frost
2021-03-24 – 2022-08-31 · Osteopenia
What this study did
Phase 1 (55)
Type 2 Diabetes
NCT05071898 · University of Maryland, Baltimore
2022-04-11 – 2028-04 · Obesity, Diabetes Type 2
What this study did
NCT06403761 · Novo Nordisk A/S
2024-05-06 – 2026-02-02 · Diabetes Mellitus, Type 2
What this study did
NCT06642584 · Novo Nordisk A/S
2024-10-15 – 2025-08-13 · Healthy Volunteers Type 2 Diabetes
What this study did
NCT06422624 · Bostal Drug Delivery Co., Ltd
2024-08 – 2024-11 · Diabetes Mellitus, Type 2
What this study did
NCT04032197 · Novo Nordisk A/S
2019-08-12 – 2023-06-06 · Diabetes Mellitus, Type 2
What this study did
NCT05689099 · Novo Nordisk A/S
2023-01-17 – 2023-05-30 · Diabetes Mellitus, Type 2, Healthy Participants
What this study did
NCT05129891 · Novo Nordisk A/S
2021-11-03 – 2023-05-04 · Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes
What this study did
NCT05435677 · Novo Nordisk A/S
2022-06-22 – 2023-04-25 · Diabetes Mellitus, Type 2
What this study did
NCT05249881 · Aga Khan University
2022-03-10 – 2022-12 · Diabetes Mellitus, Type 2, Weight Change, Body
What this study did
NCT05498610 · Novo Nordisk A/S
2022-08-11 – 2022-10-12 · Diabetes Mellitus, Type 2
What this study did
NCT05153564 · Novo Nordisk A/S
2021-12-13 – 2022-09-01 · Diabetes Mellitus, Type 2
What this study did
NCT05232708 · Novo Nordisk A/S
2022-01-19 – 2022-08-30 · Healthy Volunteers (Diabetes Mellitus, Type 2)
What this study did
NCT04259801 · Novo Nordisk A/S
2020-02-17 – 2022-03-16 · Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
What this study did
NCT05046873 · Novo Nordisk A/S
2021-09-06 – 2022-01-05 · Diabetes Mellitus, Type 2
What this study did
NCT04878406 · Novo Nordisk A/S
2021-05-18 – 2021-07-20 · Healthy Volunteers Type 2 Diabetes
What this study did
NCT04152915 · Novo Nordisk A/S
2019-11-25 – 2020-05-25 · Healthy Volunteers, Diabetes Mellitus, Type 2
What this study did
NCT03789578 · Novo Nordisk A/S
2019-01-17 – 2019-10-10 · Diabetes Mellitus, Type 2
What this study did
NCT03598621 · Novo Nordisk A/S
2018-07-23 – 2019-01-17 · Diabetes Mellitus, Type 2
What this study did
NCT03638778 · Novo Nordisk A/S
2018-08-17 – 2018-12-05 · Diabetes Mellitus, Type 2
What this study did
NCT03288740 · Novo Nordisk A/S
2017-09-21 – 2018-08-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03466567 · Novo Nordisk A/S
2018-03-15 – 2018-07-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02147431 · Novo Nordisk A/S
2014-05-21 – 2015-05-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02212067 · Novo Nordisk A/S
2014-08-11 – 2015-05-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02146079 · Novo Nordisk A/S
2014-05-21 – 2014-10-20 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT02022254 · Novo Nordisk A/S
2013-12-17 – 2014-08-28 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01866748 · Novo Nordisk A/S
2013-05 – 2014-04 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01686945 · Novo Nordisk A/S
2012-09-19 – 2013-04-08 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01572753 · Novo Nordisk A/S
2012-04-12 – 2012-09-08 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01324505 · Novo Nordisk A/S
2011-03 – 2012-01 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01272973 · Novo Nordisk A/S
2011-01 – 2011-07 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT00833716 · Novo Nordisk A/S
2009-02-02 – 2010-07-26 · Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
What this study did
NCT00813020 · Novo Nordisk A/S
2009-01 – 2009-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03144271 · Novo Nordisk A/S
2007-06-11 – 2007-10-08 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
Other / comorbidity
NCT07772960 · Yale University
2026-10-01 – 2031-10-31 · Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
What this study did
NCT07627191 · University of Arizona
2026-10-07 – 2028-06-30 · Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
What this study did
NCT06222437 · Methodist Health System
2026-02 – 2027-02 · Polycystic Ovary Syndrome
What this study did
NCT07223983 · Yale University
2026-03-26 – 2027-02 · Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
What this study did
NCT07087795 · Novo Nordisk A/S
2025-07-01 – 2026-09-25 · Diabetes Mellitus, Type 1
What this study did
NCT06149260 · Second Xiangya Hospital of Central South University
2024-02-29 – 2024-12 · Scleroderma, Systemic, Fibrosis, Semaglutide
What this study did
NCT06699329 · Merck Sharp & Dohme LLC
2024-01-22 – 2024-05-24 · Healthy
What this study did
NCT05996874 · Novo Nordisk A/S
2023-08-12 – 2024-04-18 · Healthy Participants
What this study did
NCT06097390 · Novo Nordisk A/S
2023-09-28 – 2024-03-27 · Healthy Participants
What this study did
NCT05429593 · Novo Nordisk A/S
2022-06-22 – 2023-04-13 · Healthy Volunteers
What this study did
NCT03357380 · Novo Nordisk A/S
2017-11-28 – 2020-03-20 · Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease
What this study did
NCT02557620 · Novo Nordisk A/S
2015-09 – 2016-04 · Diabetes, Healthy
What this study did
NCT02064348 · Novo Nordisk A/S
2014-02-26 – 2015-04-23 · Diabetes, Healthy
What this study did
NCT02243098 · Novo Nordisk A/S
2014-09-16 – 2015-04-07 · Diabetes, Healthy
What this study did
NCT02079870 · Novo Nordisk A/S
2014-03-06 – 2015-01-07 · Diabetes, Metabolism and Nutrition Disorder, Obesity
What this study did
Phase 4 (52)
Atherosclerotic Cardiovascular Disease
NCT07617155 · Peking Union Medical College Hospital
2026-09 – 2028-12 · Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing, Hypertriglyceridemia
What this study did
NCT07073053 · Taipei Veterans General Hospital, Taiwan
2025-10-01 – 2028-07-31 · Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes, Coronary Arterial Disease (CAD)
What this study did
NCT05870462 · Canadian Medical and Surgical Knowledge Translation Research Group
2023-04-29 – 2024-12 · Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
What this study did
NCT03985384 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2019-04-30 – 2022-12-27 · Type 2 Diabetes, Coronary Artery Disease
What this study did
Chronic Kidney Disease
NCT07900438 · Novo Nordisk A/S
2026-10-12 – 2030-01-24 · Cardiovascular Risk, Chronic Kidney Disease
What this study did
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
DIALYSIS-TIR Studyactive not recruiting
NCT06042153 · University of Texas Southwestern Medical Center
2023-12-05 – 2028-09 · Type 2 Diabetes, End Stage Renal Disease on Dialysis
What this study did
NCT07239570 · Peter Rossing
2025-06-20 – 2028-06 · Chronic Kidney Disease(CKD)
What this study did
NCT07017270 · Unity Health Toronto
2025-11-27 – 2027-09 · Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
What this study did
NCT06954090 · Steno Diabetes Center Copenhagen
2025-11-20 – 2027-05-31 · Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
What this study did
Type 2 Diabetes
NCT07485062 · Western University, Canada
2026-09-01 – 2029-05-01 · Type 2 Diabetes, Cognitive Decline in Older Adults
What this study did
NCT06706284 · Marzieh Salehi
2025-04-11 – 2029-03-01 · Spinal Cord Injuries, Type 2 Diabetes
What this study did
NCT06461377 · The First Affiliated Hospital with Nanjing Medical University
2024-06-13 – 2027-12-31 · Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
What this study did
NCT07314684 · Federico II University
2025-09-08 – 2027-03-08 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT05780905 · University of Washington
2024-01-11 – 2026-12-31 · Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
What this study did
NCT07165158 · The First Affiliated Hospital of Xiamen University
2025-09-15 – 2026-12-31 · Osteoporosis, Osteoporosis Fracture, T2DM
What this study did
NCT04892199 · Anders Fink-Jensen, MD, DMSci
2021-09-01 – 2026-08-01 · Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine, GLP-1, Olanzapine
What this study did
NCT07272343 · Second Affiliated Hospital of Nanchang University
2023-02-10 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT04639414 · German Diabetes Center
2021-03-26 – 2025-11-17 · Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
What this study did
NCT04854083 · Kirsi Pietiläinen
2022-02-17 – 2025-08 · Type2 Diabetes
What this study did
NCT04126603 · Sabyasachi Sen
2019-08-01 – 2025-05-14 · Diabetes Mellitus, Type 2
What this study did
NCT05303857 · University of Erlangen-Nürnberg Medical School
2022-03-03 – 2025-04-17 · Diabetes Mellitus, Type 2
What this study did
NCT06243536 · University Hospital Sestre Milosrdnice
2024-02-01 – 2024-12-31 · Type 2 Diabetes, Overweight, Disordered Eating Behaviors
What this study did
NCT04979130 · University of Colorado, Denver
2022-01-01 – 2024-10-16 · Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
What this study did
NCT06475586 · University of Banja Luka
2023-05-03 – 2024-06-10 · Psoriasis Vulgaris, Diabetes Type 2
What this study did
NCT05786521 · The University of Texas Health Science Center at San Antonio
2023-04-01 – 2024-05-20 · Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
What this study did
NCT05597202 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-01-01 – 2024-04 · Type 2 Diabetes
What this study did
NCT05533632 · Novo Nordisk A/S
2022-04-25 – 2024-01-18 · Diabetes Mellitus, Type 2
What this study did
NCT04538352 · The Cleveland Clinic
2021-01-18 – 2023-11-01 · Type 2 Diabetes
What this study did
NCT05606471 · University of Nottingham
2021-09-15 – 2023-07-28 · Type 2 Diabetes Mellitus in Obese
What this study did
NCT07732218 · Rehman Medical Institute - RMI
2022-07-04 – 2023-03-30 · Type 2 Diabetes
What this study did
NCT04624672 · Geisinger Clinic
2021-08-25 – 2022-08-17 · Diabetes Mellitus, Type 2
What this study did
NCT04061200 · Steno Diabetes Center Copenhagen
2019-11-01 – 2021-08-01 · Type 2 Diabetes With Renal Manifestations
What this study did
NCT04189848 · Novo Nordisk A/S
2019-12-03 – 2020-02-27 · Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
What this study did
NCT03724981 · Eli Lilly and Company
2018-10-18 – 2019-04-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07361874 · University of Texas Southwestern Medical Center
2026-03-05 – 2030-05-31 · Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
What this study did
NCT07389941 · University of Luebeck
2026-10 – 2029-04 · Atrial Fibrillation (AF)
What this study did
NCT06986993 · University of Oklahoma
2024-07-01 – 2028-06-30 · Tobacco Use
What this study did
NCT07483801 · Cambridge University Hospitals NHS Foundation Trust
2026-03 – 2028-04 · Cardiovascular Diseases
What this study did
NCT06908694 · Hamilton Health Sciences Corporation
2025-07-02 – 2027-10-31 · Prostate Cancer
What this study did
NCT06184633 · Rijnstate Hospital
2024-07-21 – 2027-05-01 · Atrial Fibrillation, Obesity, Weight Loss
What this study did
NCT07251556 · Chinese University of Hong Kong
2025-12-01 – 2027-01-01 · Psoriasis Arthritis
What this study did
NCT06959784 · China-Japan Friendship Hospital
2024-01-01 – 2026-12-31 · Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease
What this study did
NCT07513168 · Asian Institute Of Medical Sciences
2025-08-01 – 2026-12-01 · Obesity, Weight Reduction, Cardiometabolic Risk Factors
What this study did
NCT05119179 · The University of Texas Health Science Center, Houston
2021-11-22 – 2026-10-31 · PreDiabetes
What this study did
NCT07254715 · Ain Shams University
2026-01-01 – 2026-07-30 · Semaglutide-Induced Gastric Motility, Anesthesia
What this study did
NCT04873050 · Woman's
2022-01-13 – 2026-03-01 · Pre Diabetes, Postpartum Disorder
What this study did
NCT05813249 · Zagazig University
2023-02-15 – 2024-04-01 · Non-alcoholic Fatty Liver Disease
What this study did
Early phase / not applicable (20)
Chronic Kidney Disease
NCT06555146 · Bispebjerg Hospital
2024-08 – 2025-03 · Diabetes Mellitus, Type 2, Kidney Disease, Chronic
What this study did
Type 2 Diabetes
NCT05501483 · Karolinska Institutet
2023-02-08 – 2032-12-31 · Type 2 Diabetes
What this study did
NCT07065383 · University of Aberdeen
2025-08-01 – 2028-07-31 · Diabetes Mellitus Type 2
What this study did
NCT07317115 · GT Metabolic Solutions, Inc.
2026-03-18 – 2028-06 · Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)
What this study did
NCT07677995 · University of Ulster
2026-09 – 2027-02 · Type 2 Diabetes, Cardiovascular Disease, Omega-3 Fatty Acids
What this study did
NCT07570810 · Shanghai Jiao Tong University School of Medicine
2026-06-01 – 2026-12-31 · Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease
What this study did
NCT07847593 · Nordic Biotic Sp. z o.o.
2025-07-09 – 2026-07-15 · Obesity (Disorder), GLP-1 Receptor Agonist Treatment, Probiotic Intervention, Diabetes Mellitus Type 2
What this study did
NCT05984238 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-08-03 – 2026-05-28 · Diabetes Mellitus, Type 2
What this study did
NCT05779644 · RenJi Hospital
2023-02-23 – 2025-02-23 · Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid
What this study did
NCT05078255 · Asger Lund, MD
2022-01-27 – 2025-01-24 · Type 2 Diabetes, Obesity
What this study did
NCT06629688 · University Hospital Dubrava
2023-11-01 – 2024-04-01 · Diabetes Mellitus Type 2, Iron Absorption
What this study did
NCT05990374 · Nanjing First Hospital, Nanjing Medical University
2023-08-01 – 2024-01-01 · Diabetes
What this study did
NCT04383197 · University of Copenhagen
2019-12-10 – 2022-08 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07586150 · Ludwig-Maximilians - University of Munich
2028-10 – 2030-12 · Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), Schizophrenia
What this study did
NCT07874932 · Morten Hostrup, PhD
2026-10-14 – 2028-04-30 · Caloric Restriction, Body Composition, Performance
What this study did
NCT07874971 · Morten Hostrup, PhD
2026-10-14 – 2028-04-30 · Caloric Restriction, Body Composition, Performance
What this study did
NCT06608433 · University Hospital, Basel, Switzerland
2025-01-16 – 2025-11-30 · Healthy Volunteer Study, HPA, Cortisol Deficiency, Adrenal Insufficiency
What this study did
NCT06292065 · Nils Vlaeminck
2024-04-16 – 2025-05-31 · Gastroparesis
What this study did
NCT06363487 · University of Oxford
2024-06-06 – 2024-12-11 · Cognitive Change
What this study did
NCT05390307 · Dasman Diabetes Institute
2023-04-01 – 2024-01-01 · Type 1 Diabetes
What this study did
Used as active comparator (43)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (23)
Type 2 Diabetes
NCT07046273 · Shandong New Time Pharmaceutical Co., LTD
2025-08-01 – 2029-02-01 · Type 2 Diabetes (T2DM)
What this study did
NCT07400107 · Novo Nordisk A/S
2026-05-20 – 2028-12-19 · Obesity, Overweight, Diabetes Mellitus, Type 2
What this study did
NCT07866066 · Amgen
2026-10-16 – 2028-12-05 · Diabetes Mellitus, Type 2
What this study did
NCT07743983 · BrightGene Bio-Medical Technology Co., Ltd.
2026-09-17 – 2028-11-30 · Type 2 Diabetes (T2DM)
What this study did
NCT07653477 · The United Bio-Technology (Hengqin) Co., Ltd.
2026-09-07 – 2028-02-29 · Type 2 Diabetes
What this study did
NCT07628985 · Carnot Laboratories
2026-09 – 2027-10 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07064486 · BrightGene Bio-Medical Technology Co., Ltd.
2025-07-04 – 2027-04-30 · Type 2 Diabetes (T2DM)
What this study did
NCT06260722 · Eli Lilly and Company
2024-02-21 – 2027-02 · Diabetes Mellitus, Type 2
What this study did
NCT07139548 · Guangdong Raynovent Biotech Co., Ltd
2025-08-31 – 2026-12-31 · T2DM
What this study did
NCT06778967 · Gan & Lee Pharmaceuticals.
2025-02-13 – 2026-09-18 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06716216 · BrightGene Bio-Medical Technology Co., Ltd.
2025-01-13 – 2026-08-25 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06649344 · Fujian Shengdi Pharmaceutical Co., Ltd.
2024-10-31 – 2026-07-18 · Type 2 Diabetes
What this study did
NCT06184568 · Innovent Biologics (Suzhou) Co. Ltd.
2024-02-29 – 2026-02-09 · Type 2 Diabetes, Obesity
What this study did
NCT06339086 · Chengdu Brilliant Pharmaceutical Co., Ltd.
2024-04 – 2025-12-30 · Type 2 Diabetes Mellitus
What this study did
NCT06045221 · Eli Lilly and Company
2023-09-22 – 2025-08-22 · Type 2 Diabetes
What this study did
NCT06161844 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-02-23 – 2025-05-14 · Type 2 Diabetes Mellitus
What this study did
NCT06739044 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2023-09-20 – 2025-02-21 · Type 2 Diabetes
What this study did
NCT05950516 · Qilu Pharmaceutical Co., Ltd.
2023-07-10 – 2025-01-22 · Type 2 Diabetes
What this study did
NCT03987919 · Eli Lilly and Company
2019-07-30 – 2021-02-15 · Type 2 Diabetes
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06975111 · University of Colorado, Denver
2026-03-01 – 2030-10-01 · Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
What this study did
Phase 2 (12)
Chronic Kidney Disease
NCT06717698 · Novo Nordisk A/S
2024-12-02 – 2026-09-17 · Chronic Kidney Disease
What this study did
NCT04515849 · AstraZeneca
2020-08-31 – 2022-03-08 · Type 2 Diabetes Mellitus, Chronic Kidney Diseases
What this study did
Type 2 Diabetes
NCT07112872 · Hoffmann-La Roche
2025-08-19 – 2028-02-05 · Type 2 Diabetes Mellitus
What this study did
NCT07923357 · Shenzhen Salubris Pharmaceuticals Co., Ltd.
2026-10-30 – 2027-11-30 · Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM
What this study did
NCT07668388 · Novo Nordisk A/S
2026-06-22 – 2027-11-15 · Diabetes Mellitus, Type 2
What this study did
NCT07415954 · Novo Nordisk A/S
2026-04-17 – 2027-10-01 · Diabetes Mellitus, Type 2
What this study did
NCT07187856 · ProGen. Co., Ltd.
2026-01 – 2026-12 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07163624 · The United Bio-Technology (Hengqin) Co., Ltd.
2025-03-22 – 2025-12-30 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06579105 · AstraZeneca
2024-10-08 – 2025-12-19 · Diabetes Mellitus, Type 2
What this study did
NCT06256549 · Gan and Lee Pharmaceuticals, USA
2023-08-09 – 2024-07-20 · Type 2 Diabetes
What this study did
NCT04153929 · Boehringer Ingelheim
2020-04-30 – 2021-11-04 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT06072963 · Rutgers, The State University of New Jersey
2024-01-30 – 2028-12-01 · Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome
What this study did
Phase 1 (5)
Type 2 Diabetes
NCT06982859 · Eli Lilly and Company
2025-06-02 – 2027-01 · Diabetes Mellitus, Insulin Sensitivity
What this study did
NCT05670379 · Vivani Medical, Inc
2024-12-20 – 2025-08-21 · Overweight and Obesity, Type2diabetes
What this study did
NCT06634927 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2024-09-22 – 2025-02-12 · Type 2 Diabetes
What this study did
NCT03951753 · Eli Lilly and Company
2019-06-28 – 2021-04-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT06497049 · Geropharm
2023-06-30 – 2024-05-05 · Pharmacokinetics, Safety Issues, Bioequivalence
What this study did
Early phase / not applicable (2)
Type 2 Diabetes
NCT07713992 · Tianjin Medical University
2026-09-15 – 2028-02-01 · Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
What this study did
Studied as part of a combination product (8)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (7)
Type 2 Diabetes
NCT07282613 · Novo Nordisk A/S
2026-08-04 – 2030-03-30 · Diabetes Mellitus, Type 2
What this study did
NCT05394519 · Novo Nordisk A/S
2023-02-01 – 2025-02-03 · Overweight, Obesity, Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT05669755 · Novo Nordisk A/S
2023-03-01 – 2027-10-14 · Cardiovascular Disease
What this study did
Phase 2 (1)
Type 2 Diabetes
NCT06797869 · Novo Nordisk A/S
2025-01-29 – 2026-08-05 · Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Chronic Kidney Disease
NCT05897372 · Iain Bressendorff
2023-08-01 – 2024-09-23 · Diabetic Kidney Disease
What this study did
Type 2 Diabetes
NCT07172867 · Halia Therapeutics, Inc.
2026-01-06 – 2026-01-23 · Diabetes Mellitus, Type 2, Obesity
What this study did
Early phase / not applicable (1)
Type 2 Diabetes
NCT07599046 · Eighth Affiliated Hospital, Sun Yat-sen University
2026-04-30 – 2029-12-30 · Obesity Type 2 Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Semaglutide (Ozempic): this drugApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Saxenda)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy Tablets)
Approved(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
HenagliflozinPhase 3Small moleculeSodium-glucose cotransporter 2 (SGLT2)Reliable signal
NCT04390295: Placebo-adjusted LS mean HbA1c change at Week 24: -0.76% (5 mg) and -0.80% (10 mg) vs placebo, both P < .0001.
NCT03159052: Placebo-adjusted LS mean HbA1c change at Week 24: -0.91% (5 mg) and -0.94% (10 mg) vs placebo, both P < .001.
HR17031Phase 3PeptideInsulin receptor / GLP-1 receptor (combination)Partial signal
NCT06881264: Week 26 HbA1c change, LS mean: HR17031 -1.85% vs insulin glargine -1.06% (sponsor-reported)
NCT06871761: HbA1c change from baseline at week 26: HR17031 -1.53% vs insulin glargine -0.25%; LS-mean difference -1.29% (95% CI -1.48 to -1.10), P<0.0001 (sponsor-reported, ADA 2026)
IcoSema (Kyinsu)Phase 3PeptideInsulin receptor (basal), GLP-1 receptorPartial signal
NCT06269107: (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001)
NCT05352815: Change in Glycated Haemoglobin (HbA1c) (Baseline (Week 0), Week 52): IcoSema -1.6 Percentage point of HbA1c (Standard Deviation 0.99) vs Insulin Icodec -0.9 Percentage point of HbA1c (Standard Deviation 1.01)
Insulin Sudelidec (INS068)Phase 3PeptideInsulin receptor (basal)Partial signal
NCT05699408: Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%)
NCT05702073: Change in HbA1c at Week 26 (Study 301, basal-insulin background, n=423): insulin sudelidec (INS068) -0.70% vs insulin glargine -0.83%; between-group difference 0.13% (95% CI -0.05% to 0.31%)
Janagliflozin (Huiyoujing)Phase 3Small moleculeSGLT2Reliable signal
NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023)
JW0201Phase 3Small moleculeDipeptidyl peptidase-4 (DPP-4)Partial signal
NCT05814393: HbA1c change from baseline at Week 24: -0.83% with JW0201 (anagliptin) add-on vs -0.03% with placebo; between-group difference -0.80 percentage points (95% CI -0.95 to -0.64; P<0.0001)
Lobeglitazone (Duvie)Phase 3Small moleculePPAR-gammaWeak signal
NCT03739125: HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately.
NCT01106131: HbA1c change at week 24: -0.74% lobeglitazone vs -0.74% pioglitazone (difference 0.01%, 95% CI -0.16 to 0.18); noninferior.
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signalNo reviewed efficacy summary in this indication
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05606913: HbA1c change from baseline at Week 28: -1.61 percentage points (mazdutide 4mg) and -1.66 percentage points (mazdutide 6mg) vs -1.36 percentage points (dulaglutide 1.5mg); superiority P<.01 for both doses.
NCT05628311: HbA1c change from baseline at week 24: -1.57% (mazdutide 4mg), -2.15% (mazdutide 6mg) vs -0.14% (placebo); mazdutide superior to placebo
MDR-001
Phase 3(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Mitiglinide (Glufast)Phase 3Small moleculeSUR1 (short-acting)Partial signal
NCT01037842: Change in HbA1c from randomization to Week 16 endpoint: metformin+mitiglinide -0.7% (SD 0.6) vs metformin+placebo -0.4% (SD 0.7); difference significant at P=0.002.
NCT00461617: Change in HbA1c from baseline: mitiglinide -0.53% (wk12) / -0.77% (wk20) vs nateglinide -0.58% (wk12) / -0.71% (wk20); intergroup difference 0.05% (95% CI -0.19 to 0.30) at week 12 and 0.06% (95% CI -0.31 to 0.19) at week 20.
NoiiglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPnot yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Pegloxenatide (Fulaimei)Phase 3PeptideGLP-1 receptorReliable signal
NCT02477969: Phase 3b add-on-to-metformin trial: proportion achieving HbA1c <7.0% at week 24 was 37.4% (100μg) and 40.6% (200μg) vs 16.8% (placebo).
NCT02477865: Phase 3a monotherapy trial: HbA1c LS-mean change at week 24 was -1.02% (100μg) and -1.34% (200μg) vs -0.17% (placebo), p<0.0001.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06650007: Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo
NCT06649344: Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06589765: Primary, HbA1c change from baseline at week 32 vs dapagliflozin 10 mg (non-inferiority margin 0.4%, primary non-inferiority estimand): 30 mg -0.30% (95% CI -0.51 to -0.09), 60 mg -0.22% (95% CI -0.44 to -0.01), 90 mg -0.40% (95% CI -0.62 to -0.19); non-inferiority met for all three doses (all P<0.0001). Superiority (treatment policy estimand): 90 mg -0.25% (95% CI -0.45 to -0.05; one-sided P=0.0067), 60 mg not significant (P=0.0789).
NCT06672172: OUTSTAND-1 phase 3 T2D trial (placebo-controlled, diet-and-exercise inadequately controlled); enrollment (284) matches this listing exactly. Primary endpoint (HbA1c reduction at Week 32 vs placebo, across 30/60/90mg doses) was met: 1.40-1.68% reduction vs 0.06% for placebo.
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
Visepegenatide (PB-119)Phase 3PeptideGLP-1 receptorReliable signal
NCT04504396: Change in HbA1c from baseline: -1.25% (95% CI -1.35 to -1.16) with visepegenatide (PB-119) vs -0.68% (95% CI -0.78 to -0.59) with placebo; treatment difference -0.57% (95% CI -0.71 to -0.43), p<0.001.
NCT04504370: LSM change in HbA1c from baseline to week 24: visepegenatide (PB-119) -1.36% (95% CI -1.52 to -1.20) vs placebo -0.63% (95% CI -0.79 to -0.46); treatment difference -0.73% (95% CI -0.96 to -0.50, p<0.001)
Zovaglutide
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
DA-302168SPhase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Regor GLP-1Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SAL0150Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TE-8105
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
TifeglipronPhase 2Small moleculeGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
TTP273Phase 2Small moleculeGLP-1 receptorReliable signal
NCT02653599: Change in HbA1c from baseline at Week 12: placebo-subtracted difference -0.86 percentage points (TTP273 150 mg once daily) and -0.71 percentage points (TTP273 150 mg twice daily); placebo arm HbA1c increased 0.15 percentage points from baseline; described as a statistically significant reduction.
UtreglutidePhase 2PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ZT006
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
BMF-650
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
DehydraTECH-CBD / Semaglutide
Phase 1(overall)
CombinationOral peptide delivery platform, GLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
IBI3032
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Liraglutide (HUC2-676)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08642534
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08656795
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (DWRX5003)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
XW014Phase 1Small moleculeGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 112 furthest-along competitors are listed; 54 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(74 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Semaglutide (Ozempic) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (10)
November 2026 (2)
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2026-11-30 · NCT06954090 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2026-11-30 · NCT07570810 · CT.gov ↗
What to watch
December 2026 (8)
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2026-12 · NCT05067621 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07059377 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesEnrolling by invitation
Est. primary completion 2026-12 · NCT07677995 · CT.gov ↗
What to watch
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2026-12-31 · NCT06005012 · CT.gov ↗
What to watch
Phase 2Intestinal Mucositis, Inflammation, Chemotherapeutic ToxicityNot yet recruiting
Est. primary completion 2026-12-31 · NCT06449625 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06461377 · CT.gov ↗
What to watch
Phase 4Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular DiseaseEnrolling by invitation
Est. primary completion 2026-12-31 · NCT06959784 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07165158 · CT.gov ↗
What to watch
2027 (26)
January 2027 (4)
Phase 2Cocaine Use Disorder, HIVActive not recruiting
Est. primary completion 2027-01 · NCT06691243 · CT.gov ↗
What to watch
Phase 3Diabetes Type 1Recruiting
Est. primary completion 2027-01 · NCT06894784 · CT.gov ↗
What to watch
Phase 2Methamphetamine Use DisorderNot yet recruiting
Est. primary completion 2027-01 · NCT07509112 · CT.gov ↗
What to watch
Phase 4Psoriasis ArthritisNot yet recruiting
Est. primary completion 2027-01-01 · NCT07251556 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Alcohol Use Disorder, Weight Loss, Bariatric Surgery PatientsActive not recruiting
Est. primary completion 2027-02 · NCT07223983 · CT.gov ↗
What to watch
March 2027 (2)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-03-08 · NCT07314684 · CT.gov ↗
What to watch
Phase 2Addiction, Alcohol Use DisorderActive not recruiting
Est. primary completion 2027-03-31 · NCT06015893 · CT.gov ↗
What to watch
April 2027 (5)
Phase 4Cardiovascular DiseasesNot yet recruiting
Est. primary completion 2027-04 · NCT07483801 · CT.gov ↗
What to watch
Phase 4Atrial Fibrillation, Obesity, Weight LossActive not recruiting
Est. primary completion 2027-04-10 · NCT06184633 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-04-30 · NCT05071898 · CT.gov ↗
What to watch
Phase 3Klinefelter SyndromeRecruiting
Est. primary completion 2027-04-30 · NCT05586802 · CT.gov ↗
What to watch
Phase 2Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders …Recruiting
Est. primary completion 2027-04-30 · NCT06548490 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-06 · NCT05822609 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2027-06 · NCT07317115 · CT.gov ↗
What to watch
Phase 2Alcohol Use Disorder (AUD), HIVRecruiting
Est. primary completion 2027-06-30 · NCT07040592 · CT.gov ↗
What to watch
July 2027 (2)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-07 · NCT07017270 · CT.gov ↗
What to watch
Phase 3Acute Ischemic StrokeNot yet recruiting
Est. primary completion 2027-07-31 · NCT07030621 · CT.gov ↗
What to watch
September 2027 (2)
Phase 4Type 2 DiabetesActive not recruiting
Est. primary completion 2027-09 · NCT06042153 · CT.gov ↗
What to watch
Phase 2Opioid Use DisorderRecruiting
Est. primary completion 2027-09-01 · NCT06639464 · CT.gov ↗
What to watch
October 2027 (3)
Phase 3Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2027-10-01 · NCT05819138 · CT.gov ↗
What to watch
Phase 2Kidney Transplant RecipientsRecruiting
Est. primary completion 2027-10-01 · NCT05938712 · CT.gov ↗
What to watch
Phase 4Prostate CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT06908694 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Type 2 DiabetesActive not recruiting
Est. primary completion 2027-11-07 · NCT03811561 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2/3Type 1 Diabetes, Diabetes MellitusRecruiting
Est. primary completion 2027-12 · NCT06387199 · CT.gov ↗
What to watch
Early phase / not applicableCaloric Restriction, Body Composition, PerformanceNot yet recruiting
Est. primary completion 2027-12-30 · NCT07874932 · CT.gov ↗
What to watch
Early phase / not applicableCaloric Restriction, Body Composition, PerformanceNot yet recruiting
Est. primary completion 2027-12-31 · NCT07874971 · CT.gov ↗
What to watch
2028 (21)
January 2028 (1)
Phase 2Type 1 Diabetes MellitusNot yet recruiting
Est. primary completion 2028-01-31 · NCT07614412 · CT.gov ↗
What to watch
February 2028 (2)
Phase 3Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular TreatmentNot yet recruiting
Est. primary completion 2028-02 · NCT06788626 · CT.gov ↗
What to watch
Phase 3PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, ObeseRecruiting
Est. primary completion 2028-02-01 · NCT05819853 · CT.gov ↗
What to watch
April 2028 (3)
Phase 2Prostate Carcinoma, Recurrent Prostate CarcinomaRecruiting
Est. primary completion 2028-04-09 · NCT07202247 · CT.gov ↗
What to watch
Phase 2Diabetes type1, ObesityRecruiting
Est. primary completion 2028-04-30 · NCT06411210 · CT.gov ↗
What to watch
Phase 2Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis AddictionRecruiting
Est. primary completion 2028-04-30 · NCT07523633 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1/2Type 2 DiabetesRecruiting
Est. primary completion 2028-05 · NCT07563699 · CT.gov ↗
What to watch
Phase 4Tobacco UseRecruiting
Est. primary completion 2028-05-30 · NCT06986993 · CT.gov ↗
What to watch
Phase 2Weight GainRecruiting
Est. primary completion 2028-05-31 · NCT07325500 · CT.gov ↗
What to watch
June 2028 (3)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-06 · NCT07239570 · CT.gov ↗
What to watch
Phase 2Intracerebral HemorrhageNot yet recruiting
Est. primary completion 2028-06-14 · NCT07613437 · CT.gov ↗
What to watch
Phase 1Pancreatic Cancer, Colorectal Cancer, Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07627191 · CT.gov ↗
What to watch
July 2028 (2)
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2028-07-31 · NCT07065383 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2028-07-31 · NCT07073053 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Double DiabetesRecruiting
Est. primary completion 2028-08 · NCT05305794 · CT.gov ↗
What to watch
September 2028 (3)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2028-09 · NCT07617155 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2028-09-01 · NCT06706284 · CT.gov ↗
What to watch
Phase 2/3Type 1 Diabetes, Overweight , ObesityRecruiting
Est. primary completion 2028-09-01 · NCT07891156 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Ischemic StrokeNot yet recruiting
Est. primary completion 2028-10-31 · NCT07511543 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2028-11 · NCT07428746 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2028-12 · NCT07581145 · CT.gov ↗
What to watch
2029 (11)
January 2029 (2)
Phase 2Cocaine Use DisorderRecruiting
Est. primary completion 2029-01-28 · NCT07227948 · CT.gov ↗
What to watch
Phase 2Cannabis Use Disorder, Cue-reactivityNot yet recruiting
Est. primary completion 2029-01-30 · NCT07879612 · CT.gov ↗
What to watch
March 2029 (2)
Phase 3Alcohol Use DisorderRecruiting
Est. primary completion 2029-03-31 · NCT07218354 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4Atrial Fibrillation (AF)Not yet recruiting
Est. primary completion 2029-04 · NCT07389941 · CT.gov ↗
What to watch
May 2029 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2029-05-01 · NCT07485062 · CT.gov ↗
What to watch
June 2029 (2)
Phase 1/2Alzheimer Dementia (AD)Recruiting
Est. primary completion 2029-06 · NCT07651319 · CT.gov ↗
What to watch
Phase 2Stage 1 Diabetes Mellitus, Type 1Not yet recruiting
Est. primary completion 2029-06-01 · NCT07430332 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney FailureRecruiting
Est. primary completion 2029-07-01 · NCT06082063 · CT.gov ↗
What to watch
December 2029 (2)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2029-12-20 · NCT07900438 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2029-12-31 · NCT06058585 · CT.gov ↗
What to watch
2030 (5)
February 2030 (1)
Phase 2Methamphetamine-dependenceRecruiting
Est. primary completion 2030-02-15 · NCT07204249 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Glucose Intolerance After a Recent History of Gestational DiabetesRecruiting
Est. primary completion 2030-03 · NCT05569772 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol ExcessRecruiting
Est. primary completion 2030-05-31 · NCT07361874 · CT.gov ↗
What to watch
July 2030 (2)
Early phase / not applicableSevere Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), SchizophreniaNot yet recruiting
Est. primary completion 2030-07 · NCT07586150 · CT.gov ↗
What to watch
Phase 3Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin ResistanceNot yet recruiting
Est. primary completion 2030-07-30 · NCT07770282 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 1Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)Recruiting
Est. primary completion 2031-10-31 · NCT07772960 · CT.gov ↗
What to watch

See the full readout calendar ↗